Antibody therapies targeting Aβ slow the progression of AD dementia (1), which emphasizes therapeutic benefits associated with eliminating protein aggregation in AD, although clinical gains remain limited since fibril deposits of aggregated tau continue to be unmanaged. This evidence concerns the gene MAPT and Alzheimer disease.